Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...

For example, around 15- 20% of patients with prostate cancer lack the tumour suppressor gene PTEN, which result in disease that is difficult to treat. PTEN serves largely as a biomarker of ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation ...

Estimates for the frequency of PTEN mutations in prostate cancer vary widely, between around 15% and 60%, depending on the type and stage of the disease, but testing for the biomarker isn't ...

Previous research has shown that this pathway, called the PI3K-AKT pathway, is frequently mutated in prostate cancer. Although the most common mutation, in a gene called Pten, had already been ...

For example, advanced prostate cancer (PCa) is often linked to changes in the activity of a tumor suppressor, called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely ...

Previous research has shown that this pathway, called the PI3K-AKT pathway, is frequently mutated in prostate cancer. Although the most common mutation, in a gene called Pten, had already been ...

Utilizing the organoid model of prostate cancer, investigators performed clustered ... the inactivation of phosphatase and tensin homolog (PTEN), a tumor suppressor gene. Given the link between ...

UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy ...

Subsequent studies from other groups found that antioxidant response genes acted as oncogenes rather than tumor suppressors, prompting Trotman to explore an intriguing alternative: Could pro-oxidants ...